Skip to main content
Scarica e leggi gratis su app

TOOsonix Partners with Consultronix to Introduce its Innovative Dermatological Therapy in Poland

27 Marzo 2025

Strategic collaboration extends TOOsonix’s reach into Poland, addressing skin diseases for a population of over 37 million.

COPENHAGEN, Denmark, March 27, 2025 /PRNewswire/ — TOOsonix, a manufacturer of advanced dermatological therapy devices, has announced a strategic partnership with Consultronix, a prominent distributor of cutting-edge medical devices in Poland. The collaboration will introduce TOOsonix’s state-of-the-art focused ultrasound skin therapy to the Polish market, providing healthcare professionals with a new innovative solution for treating skin diseases.

TOOsonix’s MDR CE-marked dermatological therapy addresses a wide range of age-related skin diseases, including very common basal cell carcinoma, actinic keratosis, and seborrheic keratosis. Treatments are fast, non-invasive, without need for anesthesia or post treatment, and have higher efficacy and better aesthetic outcome than traditional procedures.

With approximately 20% of Poland’s population aged 65 and over, this partnership aims to improve care for this growing demographic affected by skin diseases. Leveraging Consultronix’s expertise and extensive network in hospitals and private clinics, the collaboration seeks to make these advanced therapies accessible to patients across the country.

“We are thrilled to partner with Consultronix to expand our presence in Central Europe,” said Torsten Bove and Tomasz Zawada, founders of TOOsonix. “Consultronix’s deep understanding of the Polish market and commitment to quality make them an ideal partner. Together, we aim to enhance patient outcomes by offering innovative dermatological solutions.”

Consultronix has extensive experience in introducing advanced medical technologies to Poland. Their established relationships with dermatology clinics and hospitals will ensure a successful rollout of TOOsonix’s products.

“We are proud to collaborate with TOOsonix,” said Piotr Smolarski, CEO of Consultronix. “Their groundbreaking dermatological therapies align perfectly with our mission to equip Polish healthcare professionals with the best tools for addressing evolving patient needs.”

This partnership marks another milestone in TOOsonix’s international expansion strategy, reinforcing its commitment to making cutting-edge dermatological therapies available across Europe.

About TOOsonix:TOOsonix pioneers high-intensity focused ultrasound technology for treating cancerous, pre-cancerous, and benign skin conditions. The company collaborates with healthcare professionals across Europe and the U.S. to deliver safe and effective solutions.More at www.toosonix.com.

About Consultronix:Consultronix is a leading distributor of medical devices in Poland with a strong focus on innovation and customer satisfaction. For over 38 years, it has been a trusted partner for healthcare professionals nationwide.More at www.consultronix.pl.

Contact:Torsten Bove Managing DirectorPh: +45 2059 2999Email: torsten.bove@toosonix.com

Logo – https://mma.prnewswire.com/media/2651738/TOOsonix_Logo.jpgLogo – https://mma.prnewswire.com/media/2651739/Consultronix_Logo.jpgPhoto – https://mma.prnewswire.com/media/2651740/TOOsonix_System_ONE_M_Device.jpgPhoto – https://mma.prnewswire.com/media/2651741/TOOsonix_System_ONE_M_Treatment.jpg

 

 

View original content:https://www.prnewswire.co.uk/news-releases/toosonix-partners-with-consultronix-to-introduce-its-innovative-dermatological-therapy-in-poland-302413165.html

La Ragione è anche su WhatsApp. Entra nel nostro canale per non perderti nulla!

Leggi anche

Nasuni Appoints Sam King as Chief Executive Officer

01 Aprile 2025
Company positions itself for next phase of growth through continued innovation BOSTON, April 1, 2…

Veeva Announces Research Site Clinical Trial Management System

01 Aprile 2025
Cloud CTMS software to improve research site efficiency and integrate seamlessly with sponsors BA…

ESTEVE firma un accordo di licenza per un trattamento del grave deficit primario del fattore di crescita insulino simile 1

01 Aprile 2025
BARCELLONA, Spagna, 1 aprile 2025 /PRNewswire/ — ESTEVE ha firmato un accordo di licenza e forni…

Il sistema Pa-100 Ast di Sysmex: la rivoluzione nella diagnosi e nel trattamento delle infezioni urinarie

01 Aprile 2025
– Norderstedt, Germania 01/04/2025 — Questo sistema riduce il tempo di diagnosi delle infezioni…

Iscriviti alla newsletter de
La Ragione

Il meglio della settimana, scelto dalla redazione: articoli, video e podcast per rimanere sempre informato.

    LEGGI GRATIS La Ragione

    GUARDA i nostri video

    ASCOLTA i nostri podcast

    REGISTRATI / ACCEDI